Targeted Drug Delivery to Lymph Nodes for Organ Transplants
Lymph Node Delivery in Transplantation
This research aims to create a new way to deliver anti-rejection medicines directly to lymph nodes in transplant patients, making them safer and more effective.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11089359 on NIH RePORTER |
What this research studies
Current anti-rejection medicines, while vital for organ transplants, can have side effects and may not always work as efficiently as needed, sometimes leading to organ failure or heart problems. This project focuses on developing a special delivery system using nanotechnology to guide these medicines precisely to the lymph nodes. By targeting the medicines directly to where they are most needed, we hope to improve their effectiveness. This approach could also help reduce unwanted side effects throughout the body, offering a better way to manage organ transplant rejection.
Who could benefit from this research
Good fit: This research is ultimately intended to benefit patients who have received organ transplants and require ongoing anti-rejection medication.
Not a fit: Patients who have not undergone organ transplantation or do not require immunoregulatory molecules would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this approach could lead to more effective anti-rejection therapies with fewer side effects, potentially improving the long-term health and survival of organ transplant recipients.
How similar studies have performed: While targeted drug delivery using nanotechnology is a promising strategy, its specific application to transplantation in this manner is still being developed.
Where this research is happening
Boston, United States
- Brigham and Women's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Abdi, Reza — Brigham and Women's Hospital
- Study coordinator: Abdi, Reza
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.